Medscape17d
Evaluating the Cost Effectiveness of Donepezil in the Treatment of Alzheimer's Disease in Germany Using Discrete Event Simulation
This research was funded by Eisai GmbH, Germany. Eisai GmbH was informed throughout the process of data collection and analyses, and contributed to the research through critical review of results ...
Nikkei Asia21d
Eisai eyes fiscal 2025 U.S. approval for home version of Alzheimer's drug
TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to ...
FiercePharma27d
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...
Krebsgesellschaft27d
Sicherer Sonnenschutz - Wie funktioniert das? Bewegung Ernährung und Krebs Acrylamid – ein krebsauslösender Stoff?
Broschüren - allgemeine Informationen zu den Herausgebern Broschüren Übergreifende Krebs-Themen Broschüren Brustkrebs Broschüren Gastrointestinale Tumoren Broschüren Urologische Tumoren Broschüren ...
Yahoo Finance29d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...
Seeking Alpha29d
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...